Bufab AB (publ) (0QRA)
London Exchange · UK · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 132.60 |
|---|---|
| 52-week range | 93.37 – 145.60 |
| Return, 1 month / 3 months | −8.7% / −3.2% |
| Return, 1 year / 3 years | +35.1% / +212.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 35 |
| Volatility (1 year) | 29.6% |
| Worst drawdown (1 year) | -16.4% |
| Average daily value traded | 3.72M SEK |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bufab is a Swedish supplier of fasteners and other small components, often called C-parts, such as screws, nuts, bolts and related hardware. The company acts as a distributor and supply chain partner, sourcing these items and managing their flow for industrial manufacturers. Its customers are mainly manufacturing businesses that need a reliable supply of small parts for their production. Bufab is based in Sweden and serves customers across several countries.
Bufab AB (publ) trades under the code 0QRA on the London Exchange in UK, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bufab AB (publ) (0QRA) trades on the London Exchange in UK. It last closed at SEK 132.60 on 23 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 822 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 35.1% and over the last three months it fell 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.6% | ||
| From 52-week high | -8.7% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.2% | ||
| 6-month return | 8.2% | ||
| 12-month return, skipping the last month | 48.0% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.4% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.72M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −7.7% |
|---|---|
| 1 month | −8.7% |
| 3 months | −3.2% |
| 6 months | +8.2% |
| 1 year | +35.1% |
| 3 years | +212.6% |
| 5 years | +140.3% |
Signals
| 50-day / 200-day average | 138.08 / 122.10 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.60 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Apr 2026 | SEK 0.4653 |
| 25 Apr 2025 | SEK 26.2500 |
| 26 Apr 2024 | SEK 25.0000 |
| 23 Oct 2023 | SEK 11.2500 |
| 21 Apr 2023 | SEK 12.5000 |
| 22 Apr 2022 | SEK 18.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.